Bausch + Lomb Corporation reports updates to its board leadership and committee assignments effective August 10, 2026. Thomas J. Appio has succeeded Brent Saunders as Chairman of the Board, while Mr. Saunders continues to serve as a director. The board has also appointed Laurence Paul, M.D. as Lead Independent Director.
On the same date, Robert Chersi joined the Audit and Risk Committee and the Talent and Compensation Committee. Dr. Paul joined the Nominating and Corporate Governance Committee and the Science and Technology Committee. John A. Paulson was named chair of the Nominating and Corporate Governance Committee, Eduardo Alfonso, M.D. as chair of the Science and Technology Committee, and Barbara Trebbi as chair of the Talent and Compensation Committee.
A shareholder of BLCO filed to potentially sell up to 52,900 shares of common stock through Fidelity Brokerage Services LLC, with trading on the NYSE targeted on or after 08/10/2026. The shares derive from multiple restricted stock vesting awards received from the issuer as compensation between 07/25/2023 and 05/05/2026, including individual vesting events of 16,131 shares on 03/01/2026 and 13,511 shares on 05/05/2026.
Bausch & Lomb Corp director Andrew C. Von Eschenbach reported two open-market sales of common shares. On August 6, 2026, he sold 12,500 shares at a weighted average price of $16.50, with individual trades ranging from $16.43 to $16.54. On August 7, 2026, he sold 6,059 shares at a weighted average price of $16.58, with trades from $16.57 to $16.60. A footnote also states that 4,364 matching restricted share units were forfeited to the issuer for no consideration in connection with his resignation from the board on August 5, 2026.
A shareholder of the company with symbol BLCO has filed to sell 52,900 shares of common stock through Fidelity Brokerage Services LLC. The proposed transaction has an aggregate value of $887,885.14 and is referenced for trading on the NYSE as of 08/10/2026.
The shares relate to multiple Restricted Stock Vesting events classified as compensation, with vesting dates between 07/25/2023 and 05/05/2026, indicating that the stock to be sold was largely acquired through equity compensation awards.
A shareholder of Bausch Lomb Corporation plans to sell 12,500 common shares, with an aggregate market value of $206,192.77. The shares are listed on the NYSE, with 357,165,246 common shares reported outstanding as of August 7, 2026.
The filing notes prior acquisitions of these shares through open market purchases for cash, including 1,695 shares on May 2, 2025 and 4,364 shares on February 27, 2026.
Stewart Andrew J. reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp reported that President, GPIC Andrew J. Stewart received an equity award tied to performance. On August 5, 2026, 16,778 common shares underlying previously granted performance stock units were earned at the 100% target level. These PSUs will vest on February 28, 2027, generally conditioned on continued employment, bringing his direct holdings to 103,211 shares.
Munsch Frederick reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp SVP, Controller and CAO Frederick Munsch reported an equity award tied to 9,091 common shares at a stated price of $0.00 per share, reflecting performance stock units that met 100% of target conditions as of August 5, 2026. These earned PSUs are scheduled to vest on February 28, 2027, subject to continued employment, bringing his directly held common shares to 98,731.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, reported an acquisition of 20,973 Common Shares at a stated price of $0.00 per share. According to the footnote, these represent common shares underlying performance stock units granted on February 28, 2024 that achieved the target performance level (100%) as of August 5, 2026. The earned PSUs will vest on February 28, 2027, generally subject to his continued employment, bringing his direct holdings to 187,350 shares. The Rule 10b5-1 trading plan checkbox was not marked.
Bausch & Lomb EVP and CFO Sam Eldessouky reported an award of 50,335 common shares at $0.00 per share, representing shares underlying performance stock units granted on February 28, 2024. After this acquisition he directly holds 393,527 common shares. The earned PSUs will vest on February 28, 2027, subject to his continued employment.
Bausch & Lomb executive Luc Bonnefoy, President, Surgical, reported acquiring 16,778 common shares linked to performance stock units under the 2022 Omnibus Incentive Plan. The PSUs achieved their 100% target performance level as of August 5, 2026 and will vest on February 28, 2027, subject to continued employment. Following this award, Bonnefoy holds 103,801 common shares directly.